-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on ArriVent BioPharma, Lowers Price Target to $29

Benzinga·10/07/2026 12:03:50
Listen to the news
BTIG analyst Jeet Mukherjee maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $42 to $29.